$PRAX

Praxis (PRAX) Q2 2026 Earnings Call Transcript

Praxis Precision Medicines (PRAX) reported Q2 2026 results on an earnings call. Cash and marketable securities rose to $1.4B at June 30, 2026. Q2 net loss was $83.7M, with $78M operating cash burn. Ulixacaltamide PDUFA is Jan. 29, 2027, relutrigine PDUFA Dec. 27, 2026. The POWER1 vormatrigine trial missed its primary endpoint.

Original reporting
Published Aug 13, 2026, 5:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 6:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Praxis (PRAX) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$PRAXNeutralMed
01

Why it matters

Key trading inputs are the reiterated PDUFA dates, the stated lack of advisory committee meetings, and the financial runway into 2028 alongside burn-rate acceleration and trial/program updates.

02

Market read

The transcript is most relevant for traders repricing FDA-timeline probabilities and near-term financing risk based on cash, burn, and regulatory process details.

03

What to watch

Investors may underweight the magnitude of operating cash burn acceleration and the reliance on commercial build-out execution (300-person field force) before launch.

Relevance 7/10Novelty 6/10Timing: during/after the Aug. 6, 2026 earnings call window

Background

Praxis Precision Medicines held its Q2 2026 financial results conference call, covering liquidity, operating expenses, and late-stage neurology pipeline regulatory timelines.

Company-level read

Ticker impact

$PRAXNeutralMedium confidence
Context

Praxis Precision Medicines reported Q2 2026 results and reiterated FDA PDUFA dates for ulixacaltamide (Jan. 29, 2027) and relutrigine (Dec. 27, 2026).

Expected impact

Near-term trading likely hinges on how investors interpret the extended relutrigine PDUFA and the POWER1 primary-endpoint miss for vormatrigine.

Evidence & confidence

The article includes multiple concrete regulatory milestones (PDUFA dates, no advisory committee planned) plus financial runway and burn rate, but it is a transcript-style disclosure without explicit new guidance numbers beyond the reported quarter metrics.

Market effects

Reinforces the biotech risk framework for neurology ASO programs, where FDA review mechanics (major amendments, advisory committee decisions) can materially affect timelines.

Limited, primarily impacts US small/mid-cap biotech sentiment and trading flows around FDA milestone expectations.

Low, as the disclosed catalysts are US FDA-specific.

Counterpoint

Despite the cash runway and FDA timeline clarity, the POWER1 primary-endpoint miss and ongoing high burn could keep risk premia elevated.

Key entities

  • Praxis Precision Medicines, Inc.

    US-listed biotech whose Q2 2026 earnings call disclosed cash runway, burn, and FDA milestone dates for ulixacaltamide and relutrigine.

  • Ulixacaltamide

    Essential tremor asset with a stated PDUFA date of Jan. 29, 2027 and no advisory committee planned.

  • Relutrigine

    SCN2A/SCN8A developmental and epileptic encephalopathies asset with PDUFA extended to Dec. 27, 2026 after a major amendment.

  • Vormatrigine

    Focal onset seizures program; POWER1 missed the primary endpoint at week 12 but met a key secondary responder endpoint.

Related articles

$PRAXMed

Show Me The Money: After An 800%+ Gain, PRAX Enters A High-Stakes Stretch

Praxis Precision Medicines (PRAX) says it is entering a key period with four late-stage assets and FDA Breakthrough Therapy Designations. Two candidates are under FDA review: Relutrigine (priority review, decision Dec 27, 2026) and Ulixacaltamide (decision Jan 29, 2027). Relutrigine peak DEE revenues are projected over $5B, Ulixacaltamide over $10B. Vormatrigine Phase 2/3 POWER1 missed a primary endpoint; POWER2 enrollment was paused and plans to restart are underway.

$PRAXHighAI 8/10

Why is Praxis Precision Medicines stock surging today?

Praxis Precision Medicines (PRAX) shares rose 9.3% pre-open after the company reported Q2 2026 results and said the FDA completed mid-cycle reviews for ulixacaltamide (PDUFA Jan 29, 2027) and relutrigine (PDUFA Dec 27, 2026) with no major safety or efficacy concerns and no advisory committee. FDA inspections had no Form 483 observations. Praxis reported about $1.4B cash and investments as of June 30, 2026 and received a third Breakthrough Therapy Designation for elsunersen.

$PRAXMed

Praxis Precision Medicines, Inc. (PRAX): Results of Operations and Financial Condition

Praxis Precision Medicines, Inc. (PRAX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 praxisq22026pr.htm EX-99.1 Document Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results Mid-cycle meeting completed for ulixacaltamide HCl; FDA identified no major safety or efficacy concerns to date and does not plan t

$PRAXMedAI 8/10

Praxis Gains After FDA Grants Breakthrough Therapy Designation To Elsunersen For SCN2A-DEE

Praxis Precision Medicines’ shares rose after the FDA granted Breakthrough Therapy Designation to Elsunersen for seizures linked to SCN2A Developmental and Epileptic Encephalopathy (SCN2A-DEE), according to the company. Based on EMBRAVE Part A, Elsunersen cut monthly seizure frequency by 77% vs sham; results were sustained up to one year. Praxis is enrolling about 30 patients in EMBRAVE3.

$PRAXMedAI 8/10

Praxis' Seizure Drug Move Towards Faster Development After Positive Trial Results - Praxis Precision Medi

Praxis Precision Medicine said the FDA granted Breakthrough Therapy Designation for elsunersen in SCN2A gain-of-function epilepsy (SCN2A-DEE), citing topline results from its randomized, sham-controlled Phase 1/2 EMBRAVE Part A trial in nine pediatric patients. The company reported seizure reductions maintained up to one year in an open-label extension and no drug-related serious adverse events up to 8 mg. EMBRAVE3 enrollment continues (~30 patients) after FDA discussions. Shares rose 4.70% to $